The Association Between Antipsychotics and Weight Gain and the Potential Role of Metformin Concomitant Use: A Retrospective Cohort Study.
antipsychotics
metformin
obesity
weight gain
weight loss
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
04
2022
accepted:
05
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
Obesity and its complications are associated with several adverse effects that may cause a serious impact on health. Antipsychotics-induced weight gain (AIWG) is one of the major, yet often neglected side effects of first and second generations antipsychotics. Importantly, several researches have shown metformin to be effective in managing weight gain especially, with AIWG. This study investigated the effect of antipsychotics use on weight gain and the theory of metformin concomitant use on the prevention of AIWG. A retrospective cohort review of the medical records of patients from the psychiatry outpatient clinics in the King Abdulaziz Medical city, a tertiary hospital in Jeddah from May 2016 to August 2021. The population of patients in Psychiatry section was 4,141. The sampling technique was a non-random consecutive sampling technique. Moreover, the included patients' records were divided to group 1 (patients on antipsychotics) and group 2 (patients using antipsychotics with Metformin). According to the study criteria, 395 patients' records were included. A total of 309 (78%) patients were using antipsychotics without metformin, which in this study were depicted as group 1. In addition, a total of 86 (22%) were using antipsychotics with metformin, which in this study were assigned as group 2. Out of Group 1 patients ( Statistical analysis revealed that patients on antipsychotics alone experienced weight gain, whereas the concomitant use of metformin showed reduction in the weight gain tendency. Thus, study outcomes indicate that concomitant use of metformin with antipsychotics might significantly reduce the AIWG.
Sections du résumé
Background
UNASSIGNED
Obesity and its complications are associated with several adverse effects that may cause a serious impact on health. Antipsychotics-induced weight gain (AIWG) is one of the major, yet often neglected side effects of first and second generations antipsychotics. Importantly, several researches have shown metformin to be effective in managing weight gain especially, with AIWG. This study investigated the effect of antipsychotics use on weight gain and the theory of metformin concomitant use on the prevention of AIWG.
Methods
UNASSIGNED
A retrospective cohort review of the medical records of patients from the psychiatry outpatient clinics in the King Abdulaziz Medical city, a tertiary hospital in Jeddah from May 2016 to August 2021. The population of patients in Psychiatry section was 4,141. The sampling technique was a non-random consecutive sampling technique. Moreover, the included patients' records were divided to group 1 (patients on antipsychotics) and group 2 (patients using antipsychotics with Metformin).
Results
UNASSIGNED
According to the study criteria, 395 patients' records were included. A total of 309 (78%) patients were using antipsychotics without metformin, which in this study were depicted as group 1. In addition, a total of 86 (22%) were using antipsychotics with metformin, which in this study were assigned as group 2. Out of Group 1 patients (
Conclusion
UNASSIGNED
Statistical analysis revealed that patients on antipsychotics alone experienced weight gain, whereas the concomitant use of metformin showed reduction in the weight gain tendency. Thus, study outcomes indicate that concomitant use of metformin with antipsychotics might significantly reduce the AIWG.
Identifiants
pubmed: 35686187
doi: 10.3389/fpsyt.2022.914165
pmc: PMC9170991
doi:
Types de publication
Journal Article
Langues
eng
Pagination
914165Informations de copyright
Copyright © 2022 Hakami, Felemban, Ahmad, Al-Samadani, Salamatullah, Baljoon, Alghamdi, Ramadani Sindi and Ahmed.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Psychopharmacol. 2015 Dec;29(12):1255-61
pubmed: 26510448
Nat Rev Endocrinol. 2011 Oct 18;8(2):114-26
pubmed: 22009159
Neuropsychiatr Dis Treat. 2017 Aug 22;13:2231-2241
pubmed: 28883731
Psychopharmacology (Berl). 2016 Jul;233(14):2629-53
pubmed: 27251130
Expert Opin Drug Saf. 2015 Jan;14(1):73-96
pubmed: 25400109
J Clin Psychiatry. 2004;65 Suppl 18:13-26
pubmed: 15600381
Obes Res. 1998 Jan;6(1):47-53
pubmed: 9526970
BMJ Open. 2014 Jan 08;4(1):e004158
pubmed: 24401727
Adv Ther. 2021 Feb;38(2):1035-1054
pubmed: 33278020
J Ayub Med Coll Abbottabad. 2011 Jan-Mar;23(1):66-9
pubmed: 22830150
Drugs. 2015 Jul;75(10):1071-94
pubmed: 26059289
Neuro Endocrinol Lett. 2009;30(2):256-61
pubmed: 19675512
Saudi Med J. 2008 Aug;29(8):1130-4
pubmed: 18690305
Schizophr Res. 2012 Jun;138(1):54-7
pubmed: 22398127
Eur Neuropsychopharmacol. 2015 Jan;25(1):1-16
pubmed: 25523882
Lancet. 2014 Jan 25;383(9914):356-67
pubmed: 24452044
J Clin Psychiatry. 2012 Jun;73(6):e749-55
pubmed: 22795214
J Clin Psychiatry. 2004;65 Suppl 18:47-56
pubmed: 15600384
Pharmacogenomics J. 2010 Oct;10(5):396-407
pubmed: 19997082
Ann Gen Psychiatry. 2008 Aug 18;7:12
pubmed: 18706110
Int J Clin Pract. 2009 Dec;63(12):1743-61
pubmed: 19840151
JAMA. 2008 Jan 9;299(2):185-93
pubmed: 18182600
Circ Res. 2016 May 27;118(11):1703-5
pubmed: 27230636
Mol Psychiatry. 2005 Jan;10(1):79-104
pubmed: 15289815
BMC Psychiatry. 2016 Oct 3;16(1):341
pubmed: 27716110
Curr Diabetes Rev. 2020;16(3):204-210
pubmed: 31146665
Am J Psychiatry. 1999 Nov;156(11):1686-96
pubmed: 10553730
Diabetes Res Clin Pract. 2017 Jun;128:40-50
pubmed: 28437734
CNS Drugs. 2005;19 Suppl 1:1-93
pubmed: 15998156
J Clin Endocrinol Metab. 2008 Nov;93(11):4299-306
pubmed: 18728175
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):490-6
pubmed: 21146575